Technical Challenges and Solutions in Process Development of Small Molecule Inhibitor

Zhen DUAN

Shanghai Taoshu Biotechnology Co., Ltd., Shanghai 200436, China

Abstract This paper analyzes challenges encountered during the scale-up production of small molecule inhibitors, focusing on synthesis efficiency, solubility/bioavailability, quality control, stability/storage, and side effect prediction/control. To address these issues, targeted solutions leveraging modern technologies are proposed and implemented: synthesis efficiency and purity were significantly enhanced through process optimization, green chemistry principles, and efficient catalysts; solubility and bioavailability were improved utilizing solid dispersion and nano-crystal technologies; process scale-up was optimized with online monitoring systems and continuous flow chemistry, ensuring product quality consistency; computer-aided drug design (CADD) was employed to predict and mitigate potential side effects. These integrated approaches effectively addressed key bottlenecks in the industrial-scale manufacturing of small molecule inhibitors.

Key words Small molecule inhibitor, Synthetic process, Solubility and bioavailability, Side effect prediction

1 Introduction

As an important category of chemical synthetic drugs, small molecule inhibitors play a vital role in modern drug research and development. Their small molecular structure enables superior cell membrane penetration, granting unique advantages for treating numerous diseases. Compared with biomacromolecule drugs, small molecule drugs facilitate oral formulation development while offering higher patient compliance and dose flexibility, thus garnering significant attention in the pharmaceutical industry[1]. However, process development for small molecule inhibitors faces persistent challenges: improving synthesis efficiency, optimizing solubility, and controlling quality fluctuations during production scale-up remain critical technical hurdles. Therefore, an in-depth analysis of these key issues and corresponding solutions holds substantial practical significance. This study aims to address these technical challenges through innovative process optimization methods, thereby providing both theoretical foundations and practical guidance for the efficient development and application of small molecule inhibitors.

2 Process flow of small molecule inhibitor

The research and development process for small molecule inhibitors encompasses key stages spanning initial drug target discovery to final regulatory approval (Fig. 1). Each phase is critical, directly impacting the drug's ultimate efficacy and market success.



Fig. 1 R & D process of small molecule inhibitor

2.1 Discovery of new chemical entities The discovery of new chemical entities marks the starting point of drug research and development, with the primary goal of identifying druggable targets. Effective target discovery provides the foundation for subsequent drug screening and optimization. Researchers identify potential targets through multiple approaches, including analysis of gene expression differences, protein interactions, and other methods, to pinpoint disease-associated molecules. Following target identification, researchers screen for preliminary promising compounds (Hits), which must exhibit specific biological activity. After iterative optimization and structural modification, lead compounds are ultimately selected. These leads typically demonstrate favorable pharmacological activity but may present challenges such as poor selectivity or high toxicity, necessitating further optimization[2].

2.2 Preclinical research Preclinical research represents a critical step prior to small-molecule inhibitors entering clinical studies, with the primary objective of evaluating the pharmacological, toxicological, and pharmacokinetic properties of these compounds. Through animal experiments, researchers can assess the absorption, distribution, metabolism, and excretion (ADME) characteristics of the drugs, as well as evaluate their toxicity and safety[3]. At this stage, preliminary studies on manufacturing process, quality control, and stability are also conducted to ensure that the drug

Received: June 2, 2025 Accepted: September 13, 2025

Zhen DUAN, master's degree.

can maintain adequate quality and stability during clinical studies. Preclinical studies provide important data to support the successful development of clinical trials.

2.3 Clinical research Clinical research is a critical stage for verifying the efficacy and safety of small-molecule inhibitors in humans. Clinical research is typically divided into Phase I, II, and III trials. Phase I trials primarily assess the drug's safety and dosage range, usually conducted in healthy volunteers. Phase II trials investigate the drug's efficacy and side effects, typically involving patients with the target disease. Phase III trials further validate the drug's efficacy, involve a larger number of participants, and are designed to confirm the therapeutic effects and adverse reactions of the drug[4]. Through these multi-phase clinical trials, the safety profile and efficacy of the drug are thoroughly validated, providing the foundation for its subsequent market approval.

2.4 New drug application (NDA) The NDA is the critical step in transitioning drugs from the clinical research stage to market approval. At this stage, the R&D team must prepare and submit detailed application materials, including the drug's chemical properties, clinical trial results, manufacturing processes, and other relevant information. Following review by drug regulatory authorities, if the drug meets all safety and efficacy requirements, it will be approved for market entry[5]. This process requires not only rigorous scientific data support but also compliance with relevant regulations and standards to ensure the lawful and compliant marketing of the drug.

3 Technical challenges in the process development of small molecule inhibitors

3.1 Improvement of synthesis efficiency and purity During the synthesis of small-molecule inhibitors, challenges such as the complexity of reaction conditions, catalyst selection, and variability in raw materials often result in products with insufficient purity or low reaction efficiency. Lower synthesis efficiency leads to increased time and cost during manufacturing, while suboptimal purity may compromise the ultimate safety and efficacy of the drug. Furthermore, impurities present during synthesis may not only increase the risk of side effects but also adversely affect the pharmacokinetic properties of the drug. Therefore, enhancing synthesis efficiency and purity is crucial to guaranteeing the quality of small-molecule inhibitors. To address these challenges, researchers typically employ methods such as optimizing reaction conditions, selecting efficient catalysts, and adjusting solvents or temperatures to improve synthesis efficiency. Concurrently, advanced separation and purification technologies, including high-performance liquid chromatography (HPLC) or recrystallization techniques, are utilized to ensure the final product meets stringent purity standards.

3.2 Low solubility and bioavailability Low solubility and bioavailability are common challenges for small-molecule inhibitors in pharmaceutical development. Many small-molecule inhibitors, particularly those with high molecular weight and complex structures, often exhibit low water solubility, which directly impacts their absorption *in vivo*. Low solubility hinders effective drug absorption across biological membranes, thereby reducing bioavailability and compromising efficacy. Therefore, strategies to enhance the solubility and bioavailability of small-molecule inhibitors represent a key issue in drug development. Common solutions include utilizing solid dispersion, nanotechnology-based approaches, such as nanosuspensions, liposome encapsulation, or other techniques to increase solubility and bioavailability by modifying the physicochemical properties of the drug, ultimately improving its therapeutic effect.

3.3 Quality control during production scale-up During the scale-up process for the production of small-molecule inhibitors, challenges in quality control are particularly prominent. Successful synthesis on a laboratory scale does not guarantee that the same level of quality can be achieved during mass production. As the production scale increases, batch-to-batch variations in raw materials, equipment differences, environmental changes, and other factors may adversely affect product quality. To ensure the high quality of small-molecule inhibitors during scale-up, the production process must be rigorously controlled. This includes real-time monitoring of each production stage and multiple quality tests of raw materials, semi-finished products, and finished products to ensure compliance with Good Manufacturing Practice (GMP) standards. In addition, implementing automatic production lines and online monitoring technology can significantly improve production consistency and controllability, reduce human errors, and ensure product quality stability.

3.4 Stability and storage Many small-molecule inhibitors may degrade during long-term storage, resulting in a reduction of active ingredients and thereby affecting the efficacy and safety of the drugs. The chemical, physical, and biological stability of drugs may be affected by environmental factors. To improve the stability of small-molecule inhibitors, drug research and development (R&D) must conduct detailed stability studies, exploring appropriate storage conditions and adding stabilizers. Common strategies to enhance stability include sealed packaging, controlling storage temperature, and adding antioxidants. These measures help extend the drug's effective period and ensure the expected therapeutic effect can be achieved throughout its usage period.

3.5 Side effect prediction and control Although small-molecule inhibitors are valuable therapeutic tools for treating many diseases owing to their compact molecular structure and enhanced penetration ability, their biological activity and metabolic pathways *in vivo* may induce certain adverse reactions. The occurrence of side effects is typically associated with the drug's target selectivity, metabolic pathways, and interactions with biomolecules. To effectively predict and control side effects, researchers frequently employ high-throughput screening, computer-aided drug design (CADD), and other technologies to assess toxicity during early-stage drug development. Furthermore, enhancing drug selectivity

and targeting can minimize off-target effects, thereby reducing side effect incidence. Comprehensive toxicological studies, integrating *in vitro* and *in vivo* experimental data, provide a robust foundation for ensuring small-molecule inhibitor safety.

4 Solutions

4.1 Optimization of synthesis process The optimization of small-molecule inhibitor synthesis requires selecting efficient catalysts and precisely controlling reaction conditions to enhance synthesis efficiency. When selecting catalysts, transition metal catalysts, ionic liquids, and organic catalysts can enhance reaction selectivity while lowering reaction temperature and shortening reaction time. Additionally, employing green chemistry principles reduces environmental impact, such as using non-toxic, renewable solvents and catalysts to minimize harmful substance emissions. In microreactor technology, through continuous reactant flow through micro-scale channels, reactants achieve thorough catalyst contact and rapidly reach thermal equilibrium, thereby suppressing by-product formation and enhancing product purity. This technology also enables reaction completion within shorter timeframes, ensuring high product purity and yield. By exact control of parameters like temperature, reactant concentration, and reaction duration, reactions proceed under optimized conditions, maximizing synthesis efficiency while reducing overreactions and by-product generation.

4.2 Solubility and stability improvement The solubility of small-molecule inhibitors can be enhanced through chemical modification of their molecular structure. Introducing hydrophilic functional groups into molecules significantly strengthens drug-water interactions and enhances solubility. Utilizing solid dispersion technology, where small-molecule drugs are mixed with hydrophilic carriers to achieve uniform molecular dispersion, increases drug specific surface area and solubility. This technology enables drug-carrier combination via solvothermal methods, spray drying, or similar processes to form stable solid dispersions. Nanotechnology plays a pivotal role in solubility enhancement by reducing drug particles to nanoscale dimensions, thereby significantly increasing solubility and absorption rates. Regarding stability, drug shelf life can be extended by optimizing storage conditions. Regulating storage environment factors such as humidity and temperature, combined with stabilizer usage, effectively slows drug degradation. Conducting chemical stability testing and implementing drug improvements prevents decomposition during storage, ensuring stability throughout the specified validity period.

4.3 Optimization of large-scale production In large-scale production, flow reaction technology must be employed to ensure the consistency of product quality. This technology can precisely control the reaction conditions, such as reaction temperature, pressure, reaction time, *etc.*, by reacting the reactants in a continuous flow reactor, thus improving the consistency and efficiency of the reaction. Compared with traditional batch production, flow reaction technology can reduce the problem of heat accumulation in the reaction and avoid excessive by-products in the long reaction time. Continuous production technology can also stably control the reaction conditions of each batch in the production process, reduce human operation errors, and thus improve the overall production efficiency. During the production process, the automatic monitoring system is used to monitor the production environment and reaction conditions in real time to ensure that the temperature, pressure, flow and other parameters are always within the set optimal range. Through combining sensors and data acquisition system, potential abnormal conditions can be found in time and adjusted automatically to ensure the stability of each link in the production process, reduce human errors and improve the consistency of product quality.

4.4 Quality control and standardization Through high performance liquid chromatography (HPLC) and mass spectrometry (MS) technology, each batch of drugs can be comprehensively analyzed to ensure the purity and quality of drugs. By separating different components, HPLC technology can detect the purity of drugs, accurately measure the content of impurities in drugs, and ensure that they meet the standards. Mass spectrometry technology can analyze the quality and structure of drug molecules, and verify the correctness of drug molecules. In addition, to ensure consistency of quality, GMP standards play a key role in production. Every production link needs to be carried out in accordance with GMP standards to ensure that the synthesis, processing, packaging and other stages of drugs meet strict quality management requirements. During the production process, all equipment and environments need to be regularly calibrated and verified to ensure that they meet production requirements and quality control standards. Through establishing a strict quality control system and combining with modern analytical technology, it is able to ensure the quality stability of products at every stage and meet the high standard requirements of the market for drugs.

4.5 Side effect prediction and control The key to side effect prediction lies in early screening by CADD technology. CADD technology evaluates the toxic potential of drugs by simulating the interaction between drug molecules and targets. In this process, the toxicity and side effects of drug molecules can be predicted by molecular docking and molecular dynamics simulation, so that potential adverse reactions can be identified at the early stage of drug development. In addition, virtual screening technology can identify potentially toxic molecules through large-scale screening of compounds in the database. Multistage implementation of toxicology studies is also critical, and the drug development process often includes testing for acute, subchronic, and chronic toxicity. Conducting these toxicological tests using *in vitro* and *in vivo* models allows for a comprehensive assessment of the safety of the drug at different doses. Through *in vivo* experiments, the effects of drugs on organs and cells can be detected, and the safety of long-term use can be evaluated. *In vitro* experiments, the effects of drugs on

cells are evaluated by cell culture and other methods to reduce the potential harm of drugs to human body.

5 Conclusions

As an important component of modern drug research and development, small molecule inhibitors play a key role in treating many diseases. With the in-depth study of these inhibitors, although they face numerous technical challenges during process development, such as difficulties in synthesis efficiency, solubility, bioavailability, manufacturing scalability, and side effect control, advances in technology continue to drive continuous improvements in their solutions. The efficiency and quality of small molecule inhibitor development have been significantly enhanced by optimizing synthesis processes, improving solubility and stability, refining manufacturing processes and quality control, and predicting side effects more accurately through computer-aided design. In the future, with the ongoing advancement of new technologies, the R & D of small molecule inhibitors are expected to become more efficient and precise, further ensuring their therapeutic efficacy and safety profiles. Overcoming these technical hurdles not only provides a theoretical foundation for drug R&D but also has far-reaching implications for the practical application of drugs and therapeutic outcomes.

References

[1] LIU S, CHEN XY, ZHANG ZA. Study on synthesis and optimization of synthesis technology of JAK inhibitor peficitinib[J]. Hans Journal of Medicinal Chemistry, 2022, 10: 172. (in Chinese).

[2] YANG C, ZHANG C, LI MY, *et al.* Research development of application of organic depressant in iron ore reverse flotation[J]. Conservation and Utilization of Mineral Resources, 2021, 41(4): 141 – 149. (in Chinese).

[3] YANG XQ, DAI JL, WU CL, *et al.* Advances in research on small molecule inhibitors of tropomyosin receptor kinase[J]. Progress in Pharmaceutical Sciences, 2023, 47(3): 194 – 206. (in Chinese).

[4] LIN XJ, HOU R, LIANG ZC, *et al.* Optimization of preparation process and functional evaluation of ACE inhibitory peptides from fermented red rice distiller's grains[J]. Fujian Agricultural Science and Technology, 2024, 55(11): 1 – 8. (in Chinese).

[5] HU JY, WANG MY, ZHANG T. An highly effective synthesis process of Chk1 inhibitor GDC-0575[J]. Guangdong Chemical Industry, 2021, 48(21): 72 – 73. (in Chinese).

(From page 14)

medicinal herbs; offer references for optimizing the development and use of Zhaoqing's herbal resources.

Through this study, there are following key implications: addressing antibiotic resistance through natural alternatives; bridging traditional knowledge with modern scientific validation; promoting local herb resources for sustainable antimicrobial solutions. The findings will contribute to both pharmaceutical development and food safety innovation while enhancing the value of regional medicinal plants.

References

[1] ZHANG J, XIE XX, FAN XD, *et al.* Systematic review of risk factors for methicillin-resistant *Staphylococcus aureus* (MRSA) bloodstream infections[J]. Drug Evaluation Research, 2023, 46(10): 2243 – 2250. (in Chinese).

[2] ZHAO YM, QIAO J. Analysis of *in vitro* antibacterial activity of 8 Chinese herbal medicines against clinically common bacterial strains[J]. Laboratory Medicine, 2019, 34(11): 987 – 990. (in Chinese).

[3] ZHEN XM, LUNDBORG CS, ZHANG ML, *et al.* Clinical and economic impact of methicillin resistant *Staphylococcus aureus*: A multicentre study in China[J]. Scientific Reports, 2020, 10(1): 3900.

[4] YANG R, LIU Y, GAO Y, *et al.* Traditional Chinese medicine as a promising strategy for combating antibiotic resistance[J]. Antibiotics, 2023, 40(9): 265 – 270.

[5] DAI CC, LIU Y, FAN L, *et al.* An alternative approach to combat multidrug resistant bacteria: New insights into traditional Chinese medicine monomers combined with antibiotics[J]. Advanced Biotechnology (Singapore), 2025, 3(1): 6 – 15.

[6] HE FY. Study on the antibacterial activity of Chinese herbal extracts and their control efficacy against kiwifruit canker[D]. Changsha: Hunan Agricultural University, 2021. (in Chinese).

[7] LI P, ZHAO C. *In vitro* antimicrobial activity of water and ethanol extracts from *Lonicera japonica* (honeysuckle)[J]. China Modern Medicine, 2010, 17(17): 48, 50. (in Chinese).

[8] LI J. Study on the antibacterial effect of ethanol extract from *Centipeda minima*[J]. Chinese Journal of Ethnomedicine and Ethnopharmacy, 2013, 22(14): 28 – 29. (in Chinese).

[9] RAI M, INGLE AP, PANDIT R, *et al.* Strategic advances in combating antimicrobial resistance: Harnessing natural products for innovative therapeutics[J]. Biotechnology Advances, 2021, 53(1): 12 – 18.

[10] ZHANG X, LI J, WANG Y, *et al.* Diterpenoids from Isodon rubescens overcome colistin resistance in Gram-negative bacteria by disrupting LPS biosynthesis[J]. Nature Communications, 2024, 15: 1 – 15.

[11] ZHANG Y, LI X, CHEN GQ, *et al.* A TCM-derived flavonoid cocktail as a broad-spectrum antibiotic adjuvant for resistant infections[J]. Science Translational Medicine, 2025, 17(735): 4492.

[12] CHU CL, OUYANG DJ, CHEN RK, *et al.* Study on the antibacterial activity of extracts from *Evodia lepta*[J]. Shandong Chemical Industry, 2024, 53(4): 30 – 32. (in Chinese).

[13] LI X, WANG Y, CHEN H, *et al.* Synergistic effects of TCM extracts with antibiotics: A disk diffusion-based screening approach[J]. Phytomedicine, 2025, 120(3): 154230 – 154241.

[14] ZHANG W, CHEN L, WANG YF, *et al.* Herbal medicine as antibiotic adjuvants: From ethnopharmacology to clinical practice[J]. Pharmacological Research, 2025, 151(33): 104589 – 104602.

[15] ZHANG Y, THOMAS E, WANG LW, *et al.* Traditional Chinese medicine in the post-antibiotic era: A global perspective[J]. The Lancet Infectious Diseases, 2024, 24(5): 567 – 579.